Building three-dimensional lung models for studying pharmacokinetics of inhaled drugs

Adv Drug Deliv Rev. 2021 Mar:170:386-395. doi: 10.1016/j.addr.2020.09.008. Epub 2020 Sep 22.

Abstract

Drug development is a critical step in the development pipeline of pharmaceutical industry, commonly performed in traditional cell culture and animal models. Though, those models hold critical gapsin the prediction and the translation of human pharmacokinetic (PK) and pharmacodynamics (PD) parameters. The advances in tissue engineering have allowed the combination of cell biology with microengineering techniques, offering alternatives to conventional preclinical models. Organ-on-a-chips and three-dimensional (3D) bioprinting models present the potentialityof simulating the physiological and pathological microenvironment of living organs and tissues, constituting this way,more realistic models for the assessment of absorption, distribution, metabolism and excretion (ADME) of drugs. Therefore, this review will focus on lung-on-a-chip and 3D bioprinting techniques for developing lung models that can be usedfor predicting PK/PD parameters.

Keywords: 3D bioprinting; Drug absorption screening; Lung-on-a-chip; Microfluidics; Organ-on-a-chip.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Inhalation
  • Animals
  • Drug Development
  • Humans
  • Lung / chemistry
  • Lung / metabolism*
  • Models, Biological*
  • Pharmaceutical Preparations / administration & dosage
  • Pharmaceutical Preparations / chemistry*
  • Printing, Three-Dimensional*
  • Tissue Engineering

Substances

  • Pharmaceutical Preparations